Drug Trial Radar · NCT05187884
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
May 3, 2022
Primary completion
Jan 1, 2025
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- St Vincent's Hospital, SydneyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) and once determiend safe then up to 6 months after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.
Conditions
- Ocular Melanoma
Interventions
DarovasertibDrug
Oral Darovasertib 300 mg tablets twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety of a up to a 56-day course of Darovasertib via clinical assessment by CTCAE v5.0 guidelines for adverse event(s)Time frame: 56 days post commencement of investigational product.
- Percentage of participants that complete the 56-day treatment period.Time frame: 56 days post commencement of investigational product.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kinghorn Cancer Centre, St. Vincent's Hospital
Sydney, New South Wales, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.